WXXWY Stock Performance, Insider Transaction and News

WXXWY - WUXI BIOLOGICS (CAYMAN) INC UNS

Market Cap	23.67B	P/E	38.48	EPS this Y	-	Ern Qtrly Grth	-39.90%
Income	3.4B	Forward P/E	-	EPS next Y	-	50D Avg Chg	6.00%
Sales	17.03B	PEG	-	EPS past 5Y	-	200D Avg Chg	-13.00%
Dividend	N/A	Price/Book	0.67	EPS next 5Y	-	52W High Chg	-42.00%
Recommedations	-	Quick Ratio	2.35	Shares Outstanding	2.08B	52W Low Chg	28.00%
Insider Own	-	ROA	4.63%	Shares Float	3.62B	Beta	0.63
Inst Own	0.01%	ROE	8.90%	Shares Shorted/Prior	-/-	Price	11.16
Gross Margin	40.08%	Profit Margin	19.96%	Avg. Volume	93,132	Target Price	-
Oper. Margin	19.09%	Earnings Date	Mar 26	Volume	193,150	Change	-2.02%

Healthcare | Biotechnology | China

About WUXI BIOLOGICS (CAYMAN) INC UNS

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WUXI BIOLOGICS (CAYMAN) INC UNS News

04/29/24	WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
04/25/24	AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
03/26/24	WuXi Biologics Reports Solid 2023 Annual Results
03/22/24	WuXi Biologics Named to CDP 'A List' for Water Security
03/05/24	WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
02/21/24	WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
01/31/24	WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
01/26/24	US lawmaker moves bill to ban Chinese biotech firms from federal contracts, alleging complicity with military
01/24/24	WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
01/16/24	WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
01/10/24	WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
01/08/24	WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
12/12/23	WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
12/08/23	WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
11/22/23	WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
11/21/23	Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
11/07/23	WuXi Biologics Receives AAA MSCI ESG Rating
11/07/23	Hong Kong IPO: WuXi Biologics to spin off contract research, manufacturing unit via US$520 million deal in biotech push
10/16/23	WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
10/01/23	WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WXXWY Chatroom

Anonymous92 Posted - 03/21/24

$WXXWY bought in again today

Coolidge87 Posted - 03/20/24

$WXXWY High risk, but decided to open a small position here.

bluffmeariver Posted - 03/16/24

$WXXWY Looking to start the position

JohnTill Posted - 2 months ago

$WXXWY yikes - timed that exit well and know better to stay around when regulators have a hate on for a sector/company.

JohnTill Posted - 2 months ago

$WXXWY Out for the last of the position today at $5.27. Only a 33% profit overall on the play but given the dual risks now I am going to step aside for greener pastures. It will likely get cleared now and rocket now that I have sold but all about risk-reward. Good luck to those still long.

JohnTill Posted - 02/27/24

$WXXWY Been a nice ride - locked in KURE today on the underside touch of the 20MA and also sold a few more WXXWY at $4.80 for some decent profits. China is running and I will likely regret locking in so much but with US elections around the corner I do not want to risk a biotech surprise like the two already in play. I would rather raise a little money now while it is sunny and let the profits run. Good luck to those long.

JohnTill Posted - 02/16/24

$WXXWY Given the new political twist dumped the share bought yesterday at 3.90-3.91 plus a few more at ~4.38 for a little profit since binary risk was a little to high. Still holding but holding lighter and now with a much lower cost average. Still think it is a BS case and good company but not willing to put my neck out given two items on the plate now.